Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients

OncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010–2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaPrint scor...

Descripción completa

Detalles Bibliográficos
Autores principales: Freeman, Jincong Q., Shubeck, Sarah, Howard, Frederick M., Chen, Nan, Nanda, Rita, Huo, Dezheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164191/
https://www.ncbi.nlm.nih.gov/pubmed/37149628
http://dx.doi.org/10.1038/s41523-023-00536-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164191/
https://www.ncbi.nlm.nih.gov/pubmed/37149628
http://dx.doi.org/10.1038/s41523-023-00536-z

Ejemplares similares